205 related articles for article (PubMed ID: 17296993)
1. Metabolite findings in tumefactive demyelinating lesions utilizing short echo time proton magnetic resonance spectroscopy.
Cianfoni A; Niku S; Imbesi SG
AJNR Am J Neuroradiol; 2007 Feb; 28(2):272-7. PubMed ID: 17296993
[TBL] [Abstract][Full Text] [Related]
2. Conventional and advanced magnetic resonance imaging in tumefactive demyelination.
Saini J; Chatterjee S; Thomas B; Kesavadas C
Acta Radiol; 2011 Dec; 52(10):1159-68. PubMed ID: 22025739
[TBL] [Abstract][Full Text] [Related]
3. Utility of proton MR spectroscopy for differentiating typical and atypical primary central nervous system lymphomas from tumefactive demyelinating lesions.
Lu SS; Kim SJ; Kim HS; Choi CG; Lim YM; Kim EJ; Kim DY; Cho SH
AJNR Am J Neuroradiol; 2014 Feb; 35(2):270-7. PubMed ID: 23928144
[TBL] [Abstract][Full Text] [Related]
4. Proton MR spectroscopy of tumefactive demyelinating lesions.
Saindane AM; Cha S; Law M; Xue X; Knopp EA; Zagzag D
AJNR Am J Neuroradiol; 2002 Sep; 23(8):1378-86. PubMed ID: 12223381
[TBL] [Abstract][Full Text] [Related]
5. Metabolite findings in tumefactive demyelinating lesions utilizing short echo time proton magnetic resonance spectroscopy.
Kalis M; Bowen BC; Quencer RM
AJNR Am J Neuroradiol; 2007 Sep; 28(8):1427; author reply 1427-8. PubMed ID: 17846183
[No Abstract] [Full Text] [Related]
6. Characterization of tumefactive demyelinating lesions using MR imaging and in-vivo proton MR spectroscopy.
Malhotra HS; Jain KK; Agarwal A; Singh MK; Yadav SK; Husain M; Krishnani N; Gupta RK
Mult Scler; 2009 Feb; 15(2):193-203. PubMed ID: 19181773
[TBL] [Abstract][Full Text] [Related]
7. Characterization of intracranial mass lesions with in vivo proton MR spectroscopy.
Poptani H; Gupta RK; Roy R; Pandey R; Jain VK; Chhabra DK
AJNR Am J Neuroradiol; 1995 Sep; 16(8):1593-603. PubMed ID: 7502961
[TBL] [Abstract][Full Text] [Related]
8. Assessment of citrullinated myelin by 1H-MR spectroscopy in early-onset multiple sclerosis.
Oguz KK; Kurne A; Aksu AO; Karabulut E; Serdaroglu A; Teber S; Haspolat S; Senbil N; Kurul S; Anlar B
AJNR Am J Neuroradiol; 2009 Apr; 30(4):716-21. PubMed ID: 19147724
[TBL] [Abstract][Full Text] [Related]
9. Proton MR spectroscopy of central neurocytoma using short and long echo time: new proofs for the existence of glycine and glutamate.
Liu M; Yue Q; Isobe T; Matsumura A; Li J; Yang Z; Quan H; Xing H; Gong Q
Acad Radiol; 2012 Jul; 19(7):779-84. PubMed ID: 22503892
[TBL] [Abstract][Full Text] [Related]
10. Effect of voxel position on single-voxel MR spectroscopy findings.
Ricci PE; Pitt A; Keller PJ; Coons SW; Heiserman JE
AJNR Am J Neuroradiol; 2000 Feb; 21(2):367-74. PubMed ID: 10696025
[TBL] [Abstract][Full Text] [Related]
11. Correlation of spectroscopy and magnetization transfer imaging in the evaluation of demyelinating lesions and normal appearing white matter in multiple sclerosis.
Hiehle JF; Lenkinski RE; Grossman RI; Dousset V; Ramer KN; Schnall MD; Cohen JA; Gonzalez-Scarano F
Magn Reson Med; 1994 Sep; 32(3):285-93. PubMed ID: 7984060
[TBL] [Abstract][Full Text] [Related]
12. Proton MR spectroscopy and magnetization transfer ratio in multiple sclerosis: correlative findings of active versus irreversible plaque disease.
Kimura H; Grossman RI; Lenkinski RE; Gonzalez-Scarano F
AJNR Am J Neuroradiol; 1996 Sep; 17(8):1539-47. PubMed ID: 8883654
[TBL] [Abstract][Full Text] [Related]
13. Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques.
Arnold DL; Matthews PM; Francis GS; O'Connor J; Antel JP
Ann Neurol; 1992 Mar; 31(3):235-41. PubMed ID: 1637131
[TBL] [Abstract][Full Text] [Related]
14. Axonal damage in multiple sclerosis plaques: a combined magnetic resonance imaging and 1H-magnetic resonance spectroscopy study.
Simone IL; Tortorella C; Federico F; Liguori M; Lucivero V; Giannini P; Carrara D; Bellacosa A; Livrea P
J Neurol Sci; 2001 Jan; 182(2):143-50. PubMed ID: 11137520
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy.
Bitsch A; Bruhn H; Vougioukas V; Stringaris A; Lassmann H; Frahm J; Brück W
AJNR Am J Neuroradiol; 1999 Oct; 20(9):1619-27. PubMed ID: 10543631
[TBL] [Abstract][Full Text] [Related]
16. Proton magnetic resonance spectroscopy (MRS) of metastatic brain tumors: variations of metabolic profile.
Chernov MF; Hayashi M; Izawa M; Ono Y; Hori T
Int J Clin Oncol; 2006 Oct; 11(5):375-84. PubMed ID: 17058135
[TBL] [Abstract][Full Text] [Related]
17. Increased concentrations of glutamate and glutamine in normal-appearing white matter of patients with multiple sclerosis and normal MR imaging brain scans.
Tisell A; Leinhard OD; Warntjes JB; Aalto A; Smedby Ö; Landtblom AM; Lundberg P
PLoS One; 2013; 8(4):e61817. PubMed ID: 23613944
[TBL] [Abstract][Full Text] [Related]
18. Serial diffusion-weighted MR imaging and proton MR spectroscopy of acute large demyelinating brain lesions: case report.
Rovira A; Pericot I; Alonso J; Rio J; Grivé E; Montalban X
AJNR Am J Neuroradiol; 2002; 23(6):989-94. PubMed ID: 12063231
[TBL] [Abstract][Full Text] [Related]
19. Axonal damage but no increased glial cell activity in the normal-appearing white matter of patients with clinically isolated syndromes suggestive of multiple sclerosis using high-field magnetic resonance spectroscopy.
Wattjes MP; Harzheim M; Lutterbey GG; Klotz L; Schild HH; Träber F
AJNR Am J Neuroradiol; 2007 Sep; 28(8):1517-22. PubMed ID: 17846203
[TBL] [Abstract][Full Text] [Related]
20. Quantitative proton magnetic resonance spectroscopy of focal brain lesions.
Wilken B; Dechent P; Herms J; Maxton C; Markakis E; Hanefeld F; Frahm J
Pediatr Neurol; 2000 Jul; 23(1):22-31. PubMed ID: 10963966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
